Close

Bora Completes Acquisition of US Sterile Fill/Finish Facility From Emergent

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

FDA Plans to Deploy AI Tools for Scientific Reviews

The US Food and Drug Administration has announced plans...

The Ultimate Pain Relief Guide: Proven Tips to Manage Discomfort Naturally

Pain is something that we all go through somehow...

Bora Pharmaceuticals Co., Ltd., a a global leader in pharmaceutical manufacturing announced that it has completed the acquisition from Emergent BioSolutions of its sterile manufacturing facility in Baltimore-Camden, Maryland. The facility adds drug product fill/finish to Bora’s extensive biologics drug substance capabilities.

The newly acquired 87,000-sq. ft. facility provides drug product manufacturing services for sterile injectables and offers clinical and commercial non-viral aseptic fill/finish services of vials and pre-filled syringes on four fill lines, lyophilization, formulation development, and support services.

“Following on the heels of our recent acquisition of Upsher-Smith Laboratories, the Camden facility extends our presence in North America, expands our offering for our biologics customers, and advances us further in our goal to become a full service global CDMO,” said Bobby Sheng, Chairman and CEO of Bora Group. “We look forward to further enhancing the capabilities at the site and welcoming the hugely talented team in Camden to our global family.”

Bora completed the acquisition of Upsher-Smith Laboratories, the Minnesota-based generics manufacturer and marketer, in April 2024, adding oral dose capabilities at two facilities in Plymouth, MN and Maple Grove, MN. The Company’s extensive global CDMO network now includes ten high quality manufacturing facilities serving customers across dose forms and delivery technologies.

Latest stories